Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.
about
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateRandomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsInterleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.Role of sphingosine kinase and sphingosine-1-phosphate in inflammatory arthritisThe design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter.Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.APLAR rheumatoid arthritis treatment recommendations.A randomized placebo-controlled trial of methotrexate in psoriatic arthritisLeflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexateAdverse drug reactions caused by methotrexate in Saudi populationPharmacotherapy options in rheumatoid arthritisCertolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexateDrug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis.A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.Current immunotherapy in rheumatoid arthritis.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis.Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.Risk of liver disease in methotrexate treated patients.Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.Defining and characterizing sustained remission in patients with rheumatoid arthritis.Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in tEffects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
P2860
Q24235784-FC6BB434-D02C-4F3A-99AE-925346516D12Q26859134-320D3BF0-ACDB-4000-B222-B00ACBC9652DQ30812918-ACA18A20-9B09-4A0B-93D6-DF7AB262665BQ33431836-A5639D3F-537F-48D2-943B-2D47FB3E64B5Q34110066-CBCC34BD-6040-4096-B07A-505969E3170DQ34343286-0BD45468-66BE-48C0-BB15-4882037D3B99Q34559803-80561A82-3F43-4B34-965D-994EF9FEB367Q34758283-F0F4E6F6-2ECB-459A-9268-2F7806833244Q34878540-915FFE18-49DA-4414-B1C9-1E40A35064EFQ35554857-46C280BA-67CB-419A-8A14-D19E89AADA8DQ35654012-FD1B1738-0F2B-465E-AE5A-12061FF37BA7Q35762912-EBE47AF8-FE3C-4994-BCD6-21A2DE7C6996Q36096798-7FB4D29C-C40D-4838-B54D-4098D229E59DQ36633267-20B10DF5-5B51-428A-8B3A-BED2572E0D13Q37099103-B59CA967-AD1D-4075-8B43-31224904A89CQ37106758-B47B6F2B-86B2-47D3-91ED-2259C681E6E1Q37345837-6E6714BE-446D-4817-B0D6-F2E78646772CQ37358983-B83A69B1-726D-45EB-9057-F2E7B38F75FCQ37593506-39591F98-AF2F-44D6-A88E-465CCA29CAABQ37633796-38FDE3EB-B5A9-48D4-A4C4-F2FD34C5E0DFQ38020459-4A2548F7-0121-4381-90BD-696BA687D0F7Q38133655-C1779311-E5EA-49BC-8337-6B91EC8E9F38Q38561490-45902D78-EA7F-4D4F-938D-1C7473A588D9Q38645102-9B6997DB-057F-4AFC-9908-B8576518384AQ39032626-94726581-27D8-4558-A1DC-F15E696AC8A3Q39043284-4C5C5727-23DC-467C-879C-7A45C36C6F00Q42363647-64016040-EBD9-4A04-8DBB-BDAA9E6EA1EDQ45032600-9F1C32D5-B937-407D-9F69-B86F2801F497Q47336584-261009A4-6DA0-4617-84FF-1EEB6FCE0B00Q48030951-E231DC8B-F894-4B00-96D3-EEB8F0896EA6Q50794926-06083398-C067-4286-AD2A-6206DD383165Q56966479-B8096C25-CE83-493C-9653-AB2F27BE0799Q58766138-1F0DA85E-F954-4CAD-9875-5A96D3A5C2CF
P2860
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@ast
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@en
type
label
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@ast
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@en
prefLabel
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@ast
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@en
P2093
P2860
P31
P356
P1476
Efficacy and toxicity of metho ...... atic review and meta-analysis.
@en
P2093
C Bombardier
V Phumethum
W Katchamart
P2860
P304
P356
10.1136/ARD.2008.099861
P407
P5008
P577
2008-12-03T00:00:00Z
2009-07-01T00:00:00Z